Compare Cytokinetics Inc (CYTK) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Cytokinetics Inc trades at $62.74 (market cap $8.62B), while Vivmark Residential Common Shares of Beneficial Interest trades at $60.97 (market cap $46.41B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 5.4× Cytokinetics Inc's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays a 4.68% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vivmark Residential Common Shares of Beneficial Interest for 1 Days on average.
| CYTK | VMRK | |
|---|---|---|
Market Cap | $8.62B | $46.41B |
Volume | 2,594,626 | 6,584,008 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $70.15 |
52-Week Low | $54.76 | $57.98 |
Typical Hold Time | 19 Days | 1 Days |
Enterprise Value | $8.72B | $55.52B |
Dividend Yield | — | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
